In terms of CD8+ T cells, GEMCOVAC-19 and GEMCOVAC-OM showed a significant increase in IFNγ+CD8+ T cells (P = 0.0004 and P = 0.0009 respectively) and IL-2+CD8+ T cells (P = 0.0002 and P = 0.0001, respectively) from baseline to day 29. The gene discussed is CD8A; the disease is ocular melanoma.